Jiangxi-based pharmaceutical manufacturer selling generic and traditional-medicine drugs in China.
Jiangxi-based pharmaceutical manufacturer selling generic and traditional-medicine drugs in China.
Moat: none
Headquarters: Jiangxi, China · Employees: 2,893
Size JiangXi Tianxin Pharmaceutical (603235.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.52B, the 1503rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥23.27 on 18 Nov 2026.
Performance Over six months the shares fell 9.1%, against -11.1% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 16.3% over the last twelve months (peer median +4.1%); the operating margin is 24.4% (peer median 9.9%).
Valuation It trades at 3.5× enterprise value to sales against a peer median of 4.5× (9th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.2 points above its cost of capital (5.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.58B | CN¥2.33B | CN¥2.20B | CN¥1.87B | CN¥2.29B |
| Revenue growth | — | +6% | +17% | -18% | — |
| Gross profit | CN¥1.19B | CN¥947M | CN¥891M | CN¥689M | CN¥833M |
| EBITDA | n/a | CN¥825M | CN¥774M | CN¥550M | CN¥701M |
| Net income | CN¥552M | CN¥592M | CN¥651M | CN¥476M | CN¥622M |
| Free cash flow | CN¥381M | CN¥48.7M | -CN¥567M | CN¥194M | CN¥346M |
| Capital expenditure | CN¥326M | CN¥581M | CN¥1.07B | CN¥536M | CN¥260M |
| Total debt | CN¥549M | CN¥445M | CN¥204M | CN¥170M | CN¥68.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603235.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.0% | -3.8% | 7th lowest of 21 |
| 6-month return | -9.1% | -11.1% | 11th highest of 21 |
| Distance from 52-week high | -19.1% | -40.1% | 4th highest of 21 |
| Revenue growth (TTM) | +16.3% | +4.1% | 8th highest of 20 |
| Operating margin | 24.4% | 9.9% | highest of 20 |
| EV / Sales | 3.5× | 4.5× | 9th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -4.9% | 6.0% | 6th least demanding of 12 |
| Growth delivered (Del g) | +0.2% | +7.0% | 5th lowest of 12 |
| Hurdle (Req g minus delivered) | -5.1 pp | +10.3 pp | 5th least demanding of 12 |
| ROIC minus cost of capital | +10.2 pp | -1.3 pp | 4th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | 3.5× | -4.9% | +0.2% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 1.4× | -6.1% | +1.9% |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | 46.5× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | 17.0× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 8.9× | 36.3% | +16.6% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | 0.9× | -6.8% | +32.4% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 2.5× | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 3.1× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 4.5× | 6.0% | -4.3% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 2.0× | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 1.4× | -6.4% | +12.7% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 1.2× | -6.6% | -5.6% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 5.2× | 12.8% | -14.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 9.8× | 31.1% | -15.1% |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | 216.0× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 7.2× | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | 85,633.6× | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 3.8× | 31.0% | +16.6% |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 0.8× | -18.1% | +7.0% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | 5.6× | 42.4% | +23.0% |